Callan JMB Inc.

Callan JMB Inc.

CJMB
Callan JMB Inc. US flagNASDAQ Global Select
0.79
USD
+0.02
- -
3.46MMarket Cap
Callan JMB Inc.
CJMB
(NASDAQ Global Select)

Recent

price

0.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
FRC
5.32
3.08
1.53
- -
1.12
Revenue per Share
1.45
0.51
-0.54
- -
-2.07
Basic EPS, GAAP
2.09
1.52
0.12
- -
-1.1
Free Cash Flow per Basic Share
1.04
1.73
0.78
- -
- -
Dividend per Share
- -
- -
-0.54
- -
-2.81
Book Value per Share
3.27
2.05
0.74
- -
0.33
Tangible Book Value per Share
4
4
4
- -
5
Basic Weighted Avg Shares
23
13
7
6
5
Sales/Revenue/Turnover
27.66
16.68
-34.66
-113.44
-129.21
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
6
2
-2
-8
-10
Net Income, GAAP
1.19
1.04
- -
- -
- -
Effective Tax Rate (%)
27.32
16.52
-34.95
-139.19
-184.7
Profit Margin (%)
13
8
2
2
2
Working Capital
- -
- -
1
2
2
LT Debt
14
9
3
2
2
Total Equity
- -
18.65
- -
- -
- -
Return on Invested Capital (%)
- -
539.94
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
6
Market Capitalization
21
5
6

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4
3
3
Cash, Cash Equivalents & STI
3
2
1
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-26.64%
Free Cash Flow
- -
- -
-1,144.87%
Net Income, GAAP
- -
- -
247.32%
Sales/Revenue/Turnover
- -
- -
-12.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
2
1
1
7
2025
1
2
1
1
6
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.03
-0.19
- -
-0.54
2025
-0.32
-0.31
-0.61
- -
- -
2026
-0.59
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.79
- -
- -
- -
0.78
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Callan JMB Inc. (NASDAQ: CJMB) provides vertically integrated thermal management logistics and fulfillment services to the life sciences, healthcare, pharmaceuticals, diagnostics, food, and emergency management industries through its subsidiary Coldchain Technology Services, LLC; core offerings include proprietary reusable VIP thermal shippers in 9-inch, 12-inch, and 24-inch sizes maintaining temperatures from -40°C to +70°C without dry ice or gel packs, end-to-end fulfillment with cGMP-compliant storage and distribution, Sentry real-time GPS and temperature monitoring platform upgraded to Sentry 4 for mobile tracking in October 2025, Ship2Q ultraviolet disinfection and recertification process for shipper reuse, emergency preparedness and response solutions for vaccines and medical stockpiles, specialty packaging for perishable non-pharma goods, and technical services for quality assurance and regulatory compliance. The company serves government agencies including the City of Chicago, Oregon Health Authority, Texas Department of State Health Services, and private clients such as BioBridge Global, with operations centered in the United States and expanding internationally via Callan JMB Services (India) Private Limited established in July 2025 for temperature-controlled pharmaceutical storage and distribution in Pune, Maharashtra. Founded in 2006 and headquartered at 244 Flightline Drive in Spring Branch, Texas, Callan JMB completed a $5.12 million initial public offering on February 6, 2025. Recent developments include a joint venture with Revival Health announced May 21, 2025 to bolster supply chains for health and wellness products; appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs on April 25, 2025; extension of its Chicago contract through June 2026 with $1.5 million additional funding in July 2025 bringing total value to $9.1 million; expansion into food sampling reclamation operations and a preliminary agreement in November 2025 to install oral drug delivery manufacturing equipment at its Texas facility; support for measles outbreak responses in Texas, New Mexico, and Chicago; and a second five-year contract with Oregon Health Authority awarded February 11, 2025.

Company News

APIChat
  • Callan JMB Expands Long-Standing Public Sector Infrastructure Engagement

  • Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC

  • Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC

  • Callan JMB Successfully Deploys Rapid Redistribution of Critical Pharmaceuticals to Combat Localized Disease Outbreaks for Longstanding Customer

  • Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update

  • Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement

  • Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID

  • Callan JMB Inc. (CJMB) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript

  • Callan JMB Announces Participation in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10–11, 2026

  • Head to Head Comparison: C.H. Robinson Worldwide (NASDAQ:CHRW) versus Callan JMB (NASDAQ:CJMB)

  • Financial Review: Callan JMB (NASDAQ:CJMB) versus Lakeside (NASDAQ:LSH)

  • Callan JMB (NASDAQ:CJMB) versus Jayud Global Logistics (NASDAQ:JYD) Financial Analysis

  • Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

  • Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update

  • Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy

  • Callan JMB Upgrades Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring

  • Callan JMB Announces Participation in the LD Micro Main Event XIX Conference on October 19-21, 2025

  • Callan JMB to Participate in Upcoming September Conferences

  • Callan JMB Announces Second Quarter 2025 Financial Results and Provides Business Update

  • Callan JMB Extends Long-Term Contract with City of Chicago and Receives Increase in Funding